Stock Scorecard



Stock Summary for Bioventus Inc - Class A (BVS) - $3.98 as of 4/26/2024 9:00:55 PM EST

Total Score

8 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BVS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BVS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BVS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for BVS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for BVS

Cartilage Repair Market Anticipates Rapid Growth, Projected To Reach $2.3 Billion In 2028 As Per The Business Research Company's Cartilage Repair Global Market Report 2024 3/19/2024 3:40:00 PM
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday - Alta Equipment Group ( NYSE:ALTG ) , Despegar.com ( NYSE:DESP ) , Blend Labs ( NYSE:BLND ) 3/15/2024 2:25:00 PM
Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday - Ranpak Hldgs ( NYSE:PACK ) , Bioventus ( NASDAQ:BVS ) 3/12/2024 2:37:00 PM
PTC Therapeutics ( PTCT ) Reports Q4 Loss, Lags Revenue Estimates 2/29/2024 10:20:00 PM
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Bioventus ( NASDAQ:BVS ) 2/13/2024 2:00:00 AM
Spinal Implants and Surgical Devices Market Projected USD 4.24 Billion Growth between 2024 and 2028: Market to ... - PR Newswire 2/2/2024 5:20:00 PM
Rehabilitation Equipment Global Market to Showcase Growth at a CAGR of ~5% by 2028, Examines DelveInsight 1/22/2024 10:31:00 PM
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility - Bioventus ( NASDAQ:BVS ) 1/18/2024 9:15:00 PM
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility 1/18/2024 9:15:00 PM
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - Bioventus ( NASDAQ:BVS ) 1/12/2024 9:15:00 PM

Financial Details for BVS

Company Overview

Ticker BVS
Company Name Bioventus Inc - Class A
Country USA
Description Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Sector Name LIFE SCIENCES
Industry Name SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Most Recent Quarter 12/31/2023
Next Earnings Date 6/11/2024

Stock Price History

Last Day Price 3.98
Last Day Price Updated 4/26/2024 9:00:55 PM EST
Last Day Volume 128,204
Average Daily Volume 147,018
52-Week High 6.08
52-Week Low 0.86
Last Price to 52 Week Low 362.79%

Valuation Measures

Trailing PE N/A
Industry PE 48.42
Sector PE 56.64
5-Year Average PE 8.50
Free Cash Flow Ratio 6.86
Industry Free Cash Flow Ratio 60.10
Sector Free Cash Flow Ratio 30.65
Current Ratio Most Recent Quarter 1.53
Total Cash Per Share 0.58
Book Value Per Share Most Recent Quarter 2.74
Price to Book Ratio 2.08
Industry Price to Book Ratio 5.21
Sector Price to Book Ratio 22.15
Price to Sales Ratio Twelve Trailing Months 0.57
Industry Price to Sales Ratio Twelve Trailing Months 14.23
Sector Price to Sales Ratio Twelve Trailing Months 5.17

Share Statistics

Total Shares Outstanding 63,379,000
Market Capitalization 252,248,420
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 1.56%
Reported EPS 12 Trailing Months -1.54
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.00
Net Income Twelve Trailing Months -156,230,000
Net Income Past Year -156,230,000
Net Income Prior Year -158,704,000
Quarterly Revenue Growth YOY 7.60%
5-Year Revenue Growth 8.68%

Balance Sheet

Total Cash Most Recent Quarter 36,964,000
Total Cash Past Year 36,964,000
Total Cash Prior Year 31,814,000
Net Cash Position Most Recent Quarter -342,882,000
Net Cash Position Past Year -342,882,000
Long Term Debt Past Year 379,846,000
Long Term Debt Prior Year 418,066,000
Total Debt Most Recent Quarter 379,846,000
Equity to Debt Ratio Past Year 0.31
Equity to Debt Ratio Most Recent Quarter 0.31
Total Stockholder Equity Past Year 173,591,000
Total Stockholder Equity Prior Year 325,238,000
Total Stockholder Equity Most Recent Quarter 173,591,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.22
MACD Signal -0.14
20-Day Bollinger Lower Band 4.12
20-Day Bollinger Middle Band 4.89
20-Day Bollinger Upper Band 5.66
Beta 0.50
RSI 30.04
50-Day SMA 3.93
200-Day SMA 0.00

System

Modified 4/26/2024 8:27:19 PM EST